Heilongjiang ZBD Pharmaceutical Co Ltd Financial Flexibility Index
Heilongjiang ZBD Pharmaceutical Co Ltd financial flexibility index. Heilongjiang ZBD Pharmaceutical Co Ltd (603567) has a Financial Flexibility Index of 0.07x as of September 2025. Free cash flow of CN¥304.82 Million (operating CF CN¥283.54 Million minus capex CN¥21.27 Million) represents 0% of total liabilities (CN¥4.51 Billion). See Heilongjiang ZBD Pharmaceutical Co Ltd (603567) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Financial Flexibility Index of Heilongjiang ZBD Pharmaceutical Co Ltd (2011–2025)
Financial flexibility index of Heilongjiang ZBD Pharmaceutical Co Ltd from 2011 to 2025. Historical Financial Flexibility Index trend for Heilongjiang ZBD Pharmaceutical Co Ltd across 15 annual periods. Check how high is Heilongjiang ZBD Pharmaceutical Co Ltd's earnings quality to evaluate the quality of earnings relative to operating cash generation.
Heilongjiang ZBD Pharmaceutical Co Ltd Financial Flexibility Index by Year (2011–2025)
Heilongjiang ZBD Pharmaceutical Co Ltd financial flexibility index by year from 2011 to 2025. Year-by-year free cash flow to debt coverage for Heilongjiang ZBD Pharmaceutical Co Ltd. For the full cash flow conversion analysis, see cash efficiency ratio of Heilongjiang ZBD Pharmaceutical Co Ltd.
| Year | Flexibility Index | Free Cash Flow (CNY) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.09x | CN¥390.62 Million | CN¥322.10 Million | CN¥4.36 Billion | ▲ +12.2% |
| 2024 | 0.08x | CN¥353.46 Million | CN¥164.31 Million | CN¥4.42 Billion | ▲ +197.5% |
| 2023 | -0.08x | CN¥-362.76 Million | CN¥-457.90 Million | CN¥4.43 Billion | ▼ -583.4% |
| 2022 | 0.02x | CN¥77.48 Million | CN¥-326.79 Million | CN¥4.57 Billion | ▲ +414.2% |
| 2021 | 0.00x | CN¥14.69 Million | CN¥-433.94 Million | CN¥4.45 Billion | ▼ -98.5% |
| 2020 | 0.22x | CN¥1.02 Billion | CN¥155.18 Million | CN¥4.73 Billion | ▲ +104.0% |
| 2019 | 0.11x | CN¥399.71 Million | CN¥220.92 Million | CN¥3.77 Billion | ▼ -56.9% |
| 2018 | 0.25x | CN¥786.99 Million | CN¥367.40 Million | CN¥3.20 Billion | ▼ -59.6% |
| 2017 | 0.61x | CN¥1.35 Billion | CN¥853.19 Million | CN¥2.21 Billion | ▲ +285.0% |
| 2016 | 0.16x | CN¥334.57 Million | CN¥15.83 Million | CN¥2.11 Billion | ▲ +222.8% |
| 2015 | -0.13x | CN¥-253.93 Million | CN¥-323.90 Million | CN¥1.97 Billion | ▼ -139.6% |
| 2014 | 0.33x | CN¥466.18 Million | CN¥386.32 Million | CN¥1.43 Billion | ▲ +42.6% |
| 2013 | 0.23x | CN¥343.41 Million | CN¥174.68 Million | CN¥1.50 Billion | ▼ -52.4% |
| 2012 | 0.48x | CN¥387.34 Million | CN¥154.25 Million | CN¥808.30 Million | ▲ +1.3% |
| 2011 | 0.47x | CN¥244.49 Million | CN¥104.71 Million | CN¥516.70 Million | — |